Medline (NASDAQ:MDLN) Stock Breaks Below 200-Day Moving Average – Here’s Why

Medline (NASDAQ:MDLN – Get Free Report) passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $39.34 and traded as low as $38.28. Medline shares last traded at $39.17, with a volume of 7,542,728 shares trading hands.

Medline News Roundup

Investors following MDLN have been watching these news items:

  • Positive Sentiment: Medline and Medline Holdings plan to repurchase $200 million of shares and partnership interests from the selling stockholders at the offering price. The buyback is part of the company’s existing repurchase program, though it is small relative to the size of the offering. Medline offering announcement
  • Neutral Sentiment: Options trading was unusually active, with call volume roughly 289% above its typical level. This signals heightened investor activity but does not establish a clear direction for the stock.
  • Negative Sentiment: A law firm announced an investigation into potential securities-law violations related to reported product-quality issues and prior stock declines. This is an investigation, not a finding of wrongdoing, but it adds headline and legal uncertainty. Securities investigation announcement

Wall Street Analyst Weigh In

MDLN has been the subject of several research reports. Leerink Partners boosted their price objective on shares of Medline from $43.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, November 5th. BMO Capital Markets restated an “outperform” rating and issued a $47.00 target price on shares of Medline in a report on Thursday, August 6th. Robert W. Baird set a $42.00 target price on shares of Medline in a research report on Thursday, August 6th. TD Cowen decreased their target price on shares of Medline from $53.00 to $45.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Finally, BTIG Research reissued a “buy” rating and set a $55.00 price target on shares of Medline in a report on Thursday, November 5th. Twenty-three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Medline currently has an average rating of “Moderate Buy” and an average target price of $46.08.

View Our Latest Analysis on MDLN

Medline Trading Up 3.9%

The firm has a market capitalization of $51.51 billion and a P/E ratio of 31.14. The company has a current ratio of 4.04, a quick ratio of 2.51 and a debt-to-equity ratio of 0.65. The stock has a 50 day simple moving average of $35.49 and a 200-day simple moving average of $39.29.

Medline (NASDAQ:MDLN – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.12. The firm had revenue of $7.86 billion for the quarter. Medline had a net margin of 1.84% and a return on equity of 8.21%. On average, equities research analysts forecast that Medline will post 1.58 EPS for the current fiscal year.

Insider Buying and Selling

In other Medline news, major shareholder Private Ltd Gic sold 2,088,987 shares of the stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $35.05, for a total value of $73,218,994.35. Following the transaction, the insider directly owned 16,453,806 shares in the company, valued at approximately $576,705,900.30. This trade represents a 11.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 6,348,676 shares of company stock worth $224,525,137 over the last three months. 0.81% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Medline

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC boosted its stake in shares of Medline by 8.4% in the first quarter. Janus Henderson Group PLC now owns 11,451,861 shares of the company’s stock worth $506,546,000 after acquiring an additional 887,240 shares during the period. Banque Pictet & Cie SA raised its stake in Medline by 2.0% during the 3rd quarter. Banque Pictet & Cie SA now owns 7,455,089 shares of the company’s stock valued at $258,692,000 after purchasing an additional 142,939 shares during the period. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Medline by 233.3% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 5,000,000 shares of the company’s stock worth $222,500,000 after purchasing an additional 3,500,000 shares in the last quarter. Durable Capital Partners LP lifted its holdings in Medline by 80.2% in the 3rd quarter. Durable Capital Partners LP now owns 4,734,627 shares of the company’s stock worth $164,292,000 after purchasing an additional 2,107,306 shares in the last quarter. Finally, Unisphere Establishment boosted its stake in Medline by 50.5% in the 1st quarter. Unisphere Establishment now owns 2,482,500 shares of the company’s stock worth $110,471,000 after purchasing an additional 832,500 shares during the period.

About Medline

(Get Free Report)

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.

Read More

Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.